Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04991467
Other study ID # 2020-12561
Secondary ID R01MH126821
Status Recruiting
Phase N/A
First received
Last updated
Start date December 17, 2021
Est. completion date March 31, 2026

Study information

Verified date December 2023
Source Albert Einstein College of Medicine
Contact Chloe Roske, AB
Phone 51668472019
Email chloe.roske@einsteinmed.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For caregivers in the Bronx, the pandemic has caused unprecedented psychological distress; in addition to combating social determinants of health (SDOH), these families now face greater financial insecurity and challenges related to their school-aged children. Furthermore, social distancing requirements and limited telehealth resources for Bronx families have posed greater barriers to healthcare. Such parental distress contributes to heightened risk of transgenerational cycles of psychological stress, trauma and maltreatment. The social and economic impacts of the COVID-19 pandemic have had significant consequences for family well-being, putting parents at higher risk of experiencing distress and potentially impairing their ability to provide supportive care to their children. Although children may be less susceptible to the most damaging physical consequences of COVID-19, there are growing concerns regarding the short-and long-term impacts of pandemic-related stressors on children. The marked upheaval of family life over an extended period may make children vulnerable to mental health consequences associated with the public health crisis and infection mitigation efforts. School and childcare closures, unstable financial circumstances, social isolation and lack of support have a disproportionate, cumulative impact on parents and may undermine their capacities to provide support for their children. Importantly, a large body of evidence suggests that parental stress during times of disasters induces psychopathologies in family members including children. Further, high anxiety and depressive symptoms in parents during the pandemic have been associated with higher child abuse potential, whereas greater parental support was associated with lower perceived stress and child abuse potential. In addition to psychological impacts, stress associated with caregiving can interfere with parents' ability to maintain their own health. This multimodal study addresses key strategies to mitigate the psychological and health impact of COVID-19 in parents.


Description:

Study Design 1. Objectives We hypothesize that both the CARE program and the Valera Health app will mitigate the psychological effects of COVID-19 while enhancing access to healthcare in the Bronx. The study will take place at Montefiore Medical Center (MMC), the largest health system in the Bronx, serving predominantly racial and ethnic minority individuals from underserved families. We will focus on three vulnerable caregiver cohorts presenting with moderate stress: a) caregivers of children with psychiatric conditions (N=130); b) caregivers of children with autoimmune illnesses (N=130); c) caregivers who are frontline healthcare workers at MMC (N=130). While the latter may have more favorable SDOH than families treated at MMC, this cohort has faced unprecedented stress during the pandemic. A RCT (Stage III, NIH model) with 3 arms will test our hypothesis: a) CARE program alone; b) Valera Health app; c) CARE program and Valera Health app; Study procedures will include four surveys: at study enrollment, 6-, 12- and 24-weeks and will assess parental stress (primary outcome), reflective functioning (RF), access to healthcare, mood and anxiety and additional parent and child clinical measures. Smartphones and connectivity will be provided as needed. Aim 1. To examine the efficacy of the 12-week CARE program on caregivers' emotional health and RF. Hyp. 1. (a) Compared to the Valera Health app arm at 12- and 24-week follow-up, participation in the CARE program will result in decreased caregiver's perceived stress, increased RF, and improved caregiver's mood and anxiety symptoms. (b) Therapeutic improvements in Hyp. 1a will be mediated by RF, as it reflects mentalizing capacity. Aim 2: To examine the efficacy of the 12-week Valera Health app on caregivers' emotional health and access to healthcare. Hyp. 2. (a), The Valera Health app, will result in decreased caregiver's perceived stress, increased access to healthcare, and increased adherence to and engagement in treatment. (b) CARE program + Valera Health app arm will be superior to CARE or Valera Health app alone on all outcome measures. Exploratory Aim: (a) We will also explore the effects on outcome of providing technology and connectivity to families who lack them during the study period. (b) We will explore the relative effectiveness of our intervention among the 3 vulnerable cohorts. (c) We will also utilize machine learning approaches to explore complex patterns as predictors of outcome including COVID-19 illness/deaths, medical comorbidity, psychopathology, housing, poverty, children's school status, age, family functioning, and trauma. 2. Study Timelines Individual Subject Timeline: Participation in this research will last about 24 weeks. Participants will partake in 12 one hour group sessions that meet once per week. Participants will complete several surveys when enrolled in the study and then after 6 weeks, after 12 weeks, and after 24 weeks. Overall Timeline: Because Investigators intend to rely on a pre-existing clinical infrastructure, Investigators anticipate to be able to begin enrollment within the first six months of the study. Participants will return for 6-month follow-ups. Data analysis will occur throughout the duration of the study, along with publications and conference presentations. The likelihood that this study will be carried out as planned is very high, as all methods and collaborations are already in place.


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date March 31, 2026
Est. primary completion date March 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - All participants will be primary caregivers who present with moderate level of stress by meeting a severity score of = 14 on the Perceived Stress Scale (PSS22). - Investigators will allow primary caregivers (e.g., grandmothers and aunts) as it is common in our patient population. - Clinical cohorts will be active patients in the psychiatric and rheumatology clinics in Montefiore Medical Center (MMC). - Frontline health care providers will be those who are required to work on site at Montefiore Medical Center (MMC). Exclusion Criteria: - Serious psychiatric or substance use difficulty that, in the judgement of the PI, would preclude meaningful participation in a parent intervention. - Active child abuse/maltreatment cases. - Neurocognitive conditions that may prevent participants from accessing telehealth services. - Primary language other than Spanish or English. - Utilized a smartphone health platform similar to the Valera app.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
CARE Program and Valera Application with care manager functionality
Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
Valera Application with care manager functionality
Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
CARE Program
Participant will take part in 12 week CARE program.
Valera Application
Participant will receive the Valera health application which will provide parent education materials.
CARE Program and Valera Application
Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.

Locations

Country Name City State
United States PRIME Bronx New York

Sponsors (2)

Lead Sponsor Collaborator
Albert Einstein College of Medicine National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Multidimensional Scale of Perceived Social Support MPSS week 0
Other Multidimensional Scale of Perceived Social Support MPSS change week 24
Other Youth Outcome Questionnaire YOQ week 0
Other Youth Outcome Questionnaire YOQ change week 24
Other COVID Impact Scale COVID Impact Scale week 0
Other COVID Impact Scale COVID Impact Scale change week 12
Other COVID Impact Scale COVID Impact Scale change week 24
Other Kansas Parental Satisfaction Scale KPSS week 0
Other Kansas Parental Satisfaction Scale KPSS change week 6
Other Kansas Parental Satisfaction Scale KPSS change week 12
Other Kansas Parental Satisfaction Scale KPSS change week 24
Other Family Assessment Device-General Functioning Scale FAD week 0
Other Family Assessment Device-General Functioning Scale FAD change week 12
Other Family Assessment Device-General Functioning Scale FAD change week 24
Other Life Events Checklist LEC week 0
Other Life Events Checklist LEC change week 12
Other Life Events Checklist LEC change week 24
Other Health Related Quality of Life Caregiver Quality of Life week 0
Other Health Related Quality of Life Caregiver Quality of Life change week 24
Other PC-PTSD COVID PC-PTSD COVID week 0
Other PC-PTSD COVID PC-PTSD COVID change week 24
Other RaLES-B Discrimination week 0
Other Multidimensional assessment of emotion regulation and dysregulation DERS-18 week 0
Other Multidimensional assessment of emotion regulation and dysregulation DERS-18 change week 12
Other Multidimensional assessment of emotion regulation and dysregulation DERS-18 change week 24
Other Multidimensional Scale Of Perceived Social Support MPSS change week 12
Other PROMIS EARLY CHILDHOOD PROMIS EARLY CHILDHOOD week 0
Other PROMIS EARLY CHILDHOOD PROMIS EARLY CHILDHOOD change week 24
Other PROMIS Parent Proxy Scale PROMIS Parent Proxy Scale week 0
Other PROMIS Parent Proxy Scale PROMIS Parent Proxy Scale change week 24
Other Philadelphia ACE Philadelphia ACE week 0
Other Multidimensional Assessment of Parenting Scale (MAPS) (MAPS) week 0
Other Multidimensional Assessment of Parenting Scale (MAPS) (MAPS) change week 12
Other Multidimensional Assessment of Parenting Scale (MAPS) (MAPS) change week 24
Other Drug Abuse Screening Test DAST week 0
Other Drug Abuse Screening Test DAST change week 12
Other Drug Abuse Screening Test DAST change week 24
Other Alcohol Use Disorders Identification Test (Audit C) Audit C week 0
Other Alcohol Use Disorders Identification Test (Audit C) Audit C change week 12
Other Alcohol Use Disorders Identification Test (Audit C) Audit C change week 24
Other Treatment and Health Behavior Questionnaire Treatment and Health Behavior Questionnaire week 0
Other Treatment and Health Behavior Questionnaire Treatment and Health Behavior Questionnaire week 6
Other Treatment and Health Behavior Questionnaire Treatment and Health Behavior Questionnaire week 12
Other Treatment and Health Behavior Questionnaire Treatment and Health Behavior Questionnaire week 24
Primary Perceived Stress Perceived Stress Questionnaire week 0
Primary Perceived Stress Perceived Stress Questionnaire Change weeks 6
Primary Perceived Stress Perceived Stress Questionnaire Change week 12
Primary Perceived Stress Perceived Stress Questionnaire Change week 24
Secondary Parental Reflective Functioning Questionnaire- Child Parental Reflective Functioning Questionnaire week 0
Secondary Parental Reflective Functioning Questionnaire-Child Parental Reflective Functioning Questionnaire Change week 6
Secondary Parental Reflective Functioning Questionnaire-Child Parental Reflective Functioning Questionnaire Change week 12
Secondary Parental Reflective Functioning Questionnaire- Child Parental Reflective Functioning Questionnaire Change week 24
Secondary Parent Reflective Functioning Questionnaire-Adolescent Parental Reflective Functioning Questionnaire week 0
Secondary Parent Reflective Functioning Questionnaire-Adolescent Parental Reflective Functioning Questionnaire change week 6
Secondary Parent Reflective Functioning Questionnaire-Adolescent Parental Reflective Functioning Questionnaire change week 12
Secondary Parent Reflective Functioning Questionnaire-Adolescent Parental Reflective Functioning Questionnaire change week 24
Secondary Five Minute Speech Sample FMSS week 0
Secondary Five Minute Speech Sample FMSS Change week 6
Secondary Five Minute Speech Sample FMSS Change week 12
Secondary Five Minute Speech Sample FMSS Change week 24
Secondary Beck Depression Index BDI week 0
Secondary Beck Depression Index BDI change week 6
Secondary Beck Depression Index BDI change week 12
Secondary Beck Depression Index BDI change week 24
Secondary Beck Anxiety Index BAI Change week 0
Secondary Beck Anxiety Index BAI Change week 6
Secondary Beck Anxiety Index BAI Change week 12
Secondary Beck Anxiety Index BAI Change week 24
Secondary Beck Suicide Scale Inventory BSSI week 0
Secondary Beck Suicide Scale Inventory BSSI Change week 6
Secondary Beck Suicide Scale Inventory BSSI Change week 12
Secondary Beck Suicide Scale Inventory BSSI Change week 24
Secondary Parent Stress Index PSI-4 week 0
Secondary Parent Stress Index PSI-4 change week 12
Secondary Parent Stress Index PSI-4 change week 24
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3